- Home
- LQDA vs SNDX Comparison
LQDA vs SNDX Comparison
Compare LQDA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- SNDX
- Stock Information
- Founded
- LQDA 2004
- SNDX 2005
- Country
- LQDA United States
- SNDX United States
- Employees
- LQDA N/A
- SNDX N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- LQDA Health Care
- SNDX Health Care
- Exchange
- LQDA Nasdaq
- SNDX Nasdaq
- Market Cap
- LQDA N/A
- SNDX 1.1B
- IPO Year
- LQDA 2018
- SNDX 2016
- Fundamental
- Price
- LQDA $15.35
- SNDX $11.01
- Analyst Decision
- LQDA Strong Buy
- SNDX Strong Buy
- Analyst Count
- LQDA 7
- SNDX 11
- Target Price
- LQDA $28.67
- SNDX $35.91
- AVG Volume (30 Days)
- LQDA 1.3M
- SNDX 2.5M
- Earning Date
- LQDA 05-08-2025
- SNDX 05-05-2025
- Dividend Yield
- LQDA N/A
- SNDX N/A
- EPS Growth
- LQDA N/A
- SNDX N/A
- EPS
- LQDA N/A
- SNDX N/A
- Revenue
- LQDA $14,144,000.00
- SNDX $43,722,000.00
- Revenue This Year
- LQDA $218.03
- SNDX $263.44
- Revenue Next Year
- LQDA $243.03
- SNDX $129.44
- P/E Ratio
- LQDA N/A
- SNDX N/A
- Revenue Growth
- LQDA N/A
- SNDX N/A
- 52 Week Low
- LQDA $8.26
- SNDX $9.66
- 52 Week High
- LQDA $16.81
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- LQDA 58.74
- SNDX 40.57
- Support Level
- LQDA $15.43
- SNDX $13.14
- Resistance Level
- LQDA $16.48
- SNDX $14.24
- Average True Range (ATR)
- LQDA 0.81
- SNDX 0.96
- MACD
- LQDA 0.24
- SNDX -0.22
- Stochastic Oscillator
- LQDA 68.78
- SNDX 29.40
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.